An upstream open reading frame-encoded micropeptide facilitates progression and hypoxia tolerance by stabilizing ENO1 in hepatocellular carcinoma

Inside every living cell, a complex factory operates to turn food into energy. In healthy tissues, this process is efficient and well-regulated. However, in liver cancer, the cells often hijack this machinery, switching to a less efficient but faster way of burning sugar to fuel their rapid growth. This shift, known as metabolic reprogramming, is a hallmark of cancer and helps tumors survive in harsh environments where oxygen is scarce. For decades, scientists have focused on the large, well-known proteins that drive these changes, but recent advances in technology have revealed a hidden layer of biological instruction. Hidden within the genetic code are tiny, short segments of DNA that were once thought to be non-functional noise. These segments, called upstream open reading frames, can actually produce very small proteins, known as micropeptides, which are too short to be seen by older methods but play critical roles in how cells behave. Understanding these tiny players offers a new window into how cancer cells adapt and survive, potentially revealing fresh targets for treatment.

A team of researchers at the Third Affiliated Hospital of Guangzhou Medical University has uncovered one such tiny protein that acts as a powerful accelerator for liver cancer. They identified a micropeptide named TCEA1-45aa, which is produced from a short genetic sequence located in the 5' untranslated region of a gene called TCEA1. While the main gene is known to be active in liver cancer, this specific micropeptide had never been characterized before. The researchers found that this tiny protein is present in much higher amounts in tumor tissues compared to healthy liver tissue. When they looked at patient records, they discovered that individuals with high levels of this micropeptide tended to have a poorer outlook, suggesting it plays a significant role in the disease's progression.

To understand what this micropeptide actually does, the scientists studied it in laboratory settings. They observed that when liver cancer cells produced more of this micropeptide, the cells grew faster, moved more easily, and were better at forming new tumors. Crucially, these cells also became much more tolerant of low-oxygen conditions, a common stressor inside solid tumors. The researchers traced this ability back to a specific mechanism: the micropeptide acts as a stabilizer for a key enzyme called ENO1. This enzyme is a critical part of the sugar-burning pathway that cancer cells rely on for energy. Normally, cells have a built-in system to break down and recycle ENO1 when it is no longer needed, but the micropeptide physically binds to the enzyme and prevents this breakdown. By shielding ENO1 from being destroyed, the micropeptide ensures that the cancer cell maintains a high supply of this energy-producing tool, allowing it to thrive even when oxygen is low.

The study also revealed how the cancer cell decides to make more of this micropeptide in the first place. The process is controlled by a chemical tag added to the genetic instructions, known as an m6A modification. This tag acts like a signal that tells the cell's protein-making machinery to start reading the short genetic sequence and producing the micropeptide. The researchers found that a specific protein reader, called YTHDF3, recognizes this tag and helps recruit the necessary tools to build the micropeptide. Interestingly, when the cancer cells are exposed to low oxygen, the amount of these chemical tags increases, which in turn boosts the production of the micropeptide. This creates a feedback loop where the stress of a low-oxygen environment triggers the cell to make more of the very tool that helps it survive that stress.

Perhaps the most promising finding for future treatment is that cancer cells relying heavily on this micropeptide become unusually vulnerable to drugs that block the ENO1 enzyme. The researchers tested a specific inhibitor designed to stop ENO1 from working. In cells with high levels of the micropeptide, this drug was far more effective at stopping tumor growth than in cells with low levels. This suggests that the micropeptide does not just help the cancer grow; it also makes the cancer dependent on the specific pathway it protects. In animal models, tumors with high levels of the micropeptide shrank significantly more when treated with the ENO1 inhibitor compared to control tumors. The drug worked by shutting down the enzyme's activity, not by changing the amount of the enzyme or the micropeptide itself, proving that the micropeptide's presence creates a specific weakness that can be targeted.

This work connects several distinct biological processes into a single, coherent story. It shows how a tiny, previously overlooked protein can be produced in response to environmental stress, how it stabilizes a key metabolic enzyme, and how this entire chain of events drives the aggressive behavior of liver cancer. By mapping out this pathway, the researchers have identified a new potential biomarker that could help doctors predict which patients might respond best to treatments targeting sugar metabolism. While further studies are needed to confirm these findings in broader clinical settings, the discovery of TCEA1-45aa highlights the importance of looking beyond the major players in the cell to find the small, hidden regulators that control life and death in cancer.